Literature DB >> 20503281

Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis?

Helen McPherson1, Mark Rosenthal, Andrew Bush.   

Abstract

Pseudomonas aeruginosa (PsA) is the most common pathogen to cause chronic lung infection in children with cystic fibrosis (CF), and is associated with an increase in both morbidity and mortality. Whilst the non-mucoid strain can be eradicated, it is believed that mucoid PsA is difficult, if not impossible, to eradicate. We hypothesized that with modern and aggressive antibiotic regimes, mucoid PsA can be eradicated in children with CF. We investigated this hypothesis through a retrospective review of respiratory tract cultures of children with CF at The Royal Brompton Hospital, London. Children aged under 16 with a confirmed diagnosis of CF and mucoid PsA on respiratory tract culture during a defined 9-year period were eligible for inclusion. Respiratory tract culture results were followed up for each patient to establish whether children remained infected with mucoid PsA and specifically to identify clearance of infection. Factors which may have been associated with persistence or clearance were also sought. One hundred sixteen children had the minimum dataset, and of these patients 67 (58%) cleared mucoid PsA for more than 1 year. Of the 67 patients who cleared mucoid PsA for more than 1 year, 38 (57%) patients remained clear of mucoid PsA at the last available culture (median 30, range 2-106 clear cultures, and median 55, 12-103 months clear). We conclude that isolation of mucoid PsA does not necessarily equate to lifelong infection. We suggest that trials of eradication of mucoid PsA at first isolation are required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503281     DOI: 10.1002/ppul.21220

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  4 in total

1.  Highlights of the North American Cystic Fibrosis Conference 2009.

Authors:  Andrew M Jones; Jennifer Helm; Ruth Richmond; Emily Mason-Smith; Amanda Brennan
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Authors:  Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe
Journal:  Clin Infect Dis       Date:  2014-11-25       Impact factor: 9.079

3.  Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Robert Bradley Troxler; Wynton C Hoover; LaCrecia J Britton; Andrea M Gerwin; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2012-04-11

Review 4.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.